Evidence map›Paper›PMID 23734213›Full record

ArticlePloS one2013

Functional domains of androgen receptor coactivator p44/Mep50/WDR77and its interaction with Smad1.

Yirong Li, Liantian Tian, Martin Ligr, Garrett Daniels, Yi Peng, Xinyu Wu, Mandeep Singh, Jianjun Wei, Yongzhao Shao, Herbert Lepor and 4 more

Abstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Androgen receptor coactivators that inhibit prostate cancer growth.American journal of clinical and experimental urology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yirong LiDepartment of Pathology, New York University School of Medicine, New York, New York, USA.
Liantian Tian
Martin Ligr
Garrett Daniels
Yi Peng
Xinyu Wu
Mandeep Singh
Jianjun Wei
Yongzhao Shao
Herbert Lepor
Ruliang Xu
Zhijie Chang
Zhengxin Wang
Peng Lee

Funding

TRAINING PROGRAM IN MOLECULAR ONCOLOGY &IMMUNOLOGYT32CA009161 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L., LEVY, DAVID E · 1985 to 2020
$13.3M
Multidisciplinary Clinical and Translational Science (MCTS) Program (UL1)UL1TR000150 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LLOYD-JONES, DONALD M · 2012 to 2013
$10.1M
Signaling Pathway Alterations in the Racial Disparity of Prostate CancerU01CA149556 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LEE, PENG, ZHANG, DAVID Y · 2011 to 2016
$1.9M
NCATS NIH HHS UL1 TR000150NCI NIH HHS 1U01CA149556-01NCI NIH HHS T32 CA009161NCI NIH HHS U01 CA149556
6 · The paper itself

Abstract

p44/MEP50/WDR77 has been identified as a coactivator of androgen receptor (AR), with distinct growth suppression and promotion function in gender specific endocrine organs and their malignancies. We dissected the functional domains of p44 for protein interaction with transcription factors, transcriptional activation, as well as the functional domains in p44 related to its growth inhibition in prostate cancer. Using a yeast two-hybrid screen, we identified a novel transcription complex AR-p44-Smad1, confirmed for physical interaction by co-immunoprecipitaion and functional interaction with luciferase assays in human prostate cancer cells. Yeast two-hybrid assay revealed that the N-terminal region of p44, instead of the traditional WD40 domain at the C-terminus, mediates the interaction among p44, N-terminus of AR and full length Smad1. Although both N and C terminal domains of p44 are necessary for maximum AR transcriptional activation, the N terminal fragment of p44 alone maintains the basic effect on AR transcriptional activation. Cell proliferation assays with N- and C- terminal deletion mutations indicated that the central portion of p44 is required for nuclear p44 mediated prostate cancer growth inhibition.

Indexed as

AndrogensBinding SitesBlotting, WesternCell Line, TumorCell ProliferationChromatin ImmunoprecipitationHumansMaleMultiprotein ComplexesProstatic NeoplasmsProtein BindingReceptors, AndrogenSmad1 ProteinTranscription FactorsTwo-Hybrid System TechniquesAndrogensAR protein, humanMultiprotein ComplexesReceptors, AndrogenSmad1 ProteinTranscription FactorsWDR77 protein, human

Identifiers

PMID23734213
PMCPMC3667176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.